Ireland - English - HPRA (Health Products Regulatory Authority)

g & a licensing limited - ketorolac trometamol - eye drops solution - 0.5 %w/v

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - ketorolac trometamol - eye drops solution - 0.5 %w/v

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's goodness australia pty ltd - ascorbic acid,copper gluconate,crocus sativus,d-alpha-tocopheryl acid succinate,zinc oxide -

Singapore - English - HSA (Health Sciences Authority)

ning kwong optical company (private) limited - ophthalmology - macular pigment scanner (mpsii) is a computerized instrument for measuring a subject's macular pigment optical density. its purpose is to identify patients at risk of developing early stage age-related macular degeneration (amd).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; sucrose; water for injections; polysorbate 20 - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd) - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo) - diabetic macular oedema (dme) - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo) - visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sucrose; polysorbate 20; sodium chloride; water for injections; dibasic sodium phosphate heptahydrate - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd); - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo); - diabetic macular oedema (dme); - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo); - visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - dexamethasone - implant in applicator - dexamethasone 0.7 mg - dexamethasone - dexamethasone - ozurdex is indicated for the treatment of adult patients with:• diabetic macular oedema (dme)• macular oedema following either branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo).• inflammation of the posterior segment of the eye presenting as non-infectious uveitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - ocriplasmin 2.5 mg/ml - concentrate for injection - 2.5 mg/ml - active: ocriplasmin 2.5 mg/ml excipient: citric acid monohydrate mannitol sodium hydroxide water for injection - jetrea is indicated in adults for the treatment of vitreomacular traction (vmt), including when associated with macular hole of diameter less than or equal to 400 microns.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ranibizumab, quantity: 1.65 mg - injection, solution - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; water for injections - lucentis (ranibizumab) is indicated in adults for:,- the treatment of neovascular (wet) age-related macular degeneration (amd),- the treatment of visual impairment due to diabetic macular oedema (dme),- the treatment of proliferative diabetic retinopathy (pdr),- the treatment of visual impairment due to choroidal neovascularisation.,- the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),- the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo)

Australia - English - Department of Health (Therapeutic Goods Administration)

i-care pharma distributors pty ltd - ocriplasmin -